Link between lactation and visceral, pericardial fat
As demonstrated by multiple studies over the years, women who breastfeed have a lower risk for developing cardiovascular disease and diabetes when compared to those who don’t or… read more.
As demonstrated by multiple studies over the years, women who breastfeed have a lower risk for developing cardiovascular disease and diabetes when compared to those who don’t or… read more.
GW Pharmaceuticals plc , a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for… read more.
AstraZeneca and FibroGen, Inc. announced that the FDA informed FibroGen that it will convene a meeting of the Cardiovascular and Renal Drugs Advisory Committee to review the new… read more.
A new type of drug that helps target chemotherapy directly to cancer cells has been found to significantly increase survival of patients with the most common form of… read more.
In a SWOG Cancer Research Network trial that put three targeted drugs to the test, the small molecule inhibitor cabozantinib was found most effective in treating patients with… read more.
Lenvatinib plus pembrolizumab yields better overall survival than single-agent sunitinib when given as first-line therapy in untreated patients with metastatic kidney cancer. The combination also improved progression-free survival… read more.
Bacteria or viruses like influenza that cause pneumonia can spread across large regions of the lung over the course of hours.
People infected with COVID-19 experience a wide range of symptoms and severities, the most commonly reported including high fevers and respiratory problems.
The European Medicines Agency gave its backing to 15 new medicines at its December meeting, taking its total for the year to 96.
Article written by Bruce Sylvester The diabetes drug canagliflozin, which has already shown efficacy in slowing kidney disease, is also effective among patients with advanced kidney disease.
Article written by Bruce Sylvester Hydroxychloroquine treatment for lupus has no significant impact on heart rhythm, researchers reported on Nov 2, 2020 at the American College of Rheumatology/ACR… read more.
Article written by Bruce Sylvester Patients with chronic kidney disease have achieved improved outcomes with dapagliflozin treatment, researchers reported on October 8, 2020 in the NEJM/New England Journal… read more.